Quality problems more likely in offshore drug plants, study finds
by John GrayOhio State University
COLUMBUS, Ohio – Drugs produced in offshore manufacturing plants –- even those run by U.S. manufacturers -- pose a greater quality risk than those prepared in the mainland United States, a new study suggests.
Researchers found that drugs produced in Puerto Rican plants owned and operated by U.S. pharmaceutical firms were more likely to have quality problems than those produced by the same firm in a matched plant on the United States mainland.
No comments:
Post a Comment